Key facts
- This page summarizes Helen M. Thackray's Form 4 filing for BIOCRYST PHARMACEUTICALS INC (BCRX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 23 Dec 2024, 16:15.
Helen M. Thackray - 19 Dec 2024 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)
- Reporting relationship
- Chief R&D Officer
- Issuer ticker
- BCRX
- Reported as of
- 19 Dec 2024
- Net transaction value
- -$45,049
- SEC form
- 4
- Accepted by SEC
- 23 Dec 2024, 16:15:26 UTC
- Prior SEC filing
- 17 Dec 2024
- Next SEC filing
- 02 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alane P. Barnes, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Helen M. Thackray filed Form 4 for BIOCRYST PHARMACEUTICALS INC (BCRX) on 23 Dec 2024.
Change
- Previous filing in this sequence was filed on 17 Dec 2024.
- Current net transaction value: -$45,049.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCRX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +125,950
- Change %
- +48%
- Price
- $0.000000
- Shares after
- 390,939
- Date
- 19 Dec 2024
- Ownership
- Direct
- Footnotes
- F1
BCRX
transaction
Common Stock
Tax liability
- Transaction value
- $45,049
- Shares
- -6,096
- Change %
- -1.6%
- Price
- $7.39
- Shares after
- 384,843
- Date
- 19 Dec 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BCRX
transaction
Derivative
Emp. Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +260,950
- Change %
- Price
- $0.000000
- Shares after
- 260,950
- Date
- 19 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 260,950
- Exercise price
- $7.39
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
Footnote F2
Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person.
Footnote F3
Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.